Yeji

$BCRX

BIOCRYST PHARMACEUTICALS INC

Runway:12 mo
NasdaqMarket cap: —CIK 0000882796

Upcoming catalysts

0 surfaced

No catalysts surfaced for BCRX yet.

Drug pipeline

orladeyo
orladeyo (berotralstat)
Hereditary angioedema (HAE) in pediatric patients aged 2 to 11 years
Forodesine Hydrochloride Sterile Solution, 5 mg/mL
Leukemia
BCX9930
Complement 3 Glomerulopathy
BCX7353 capsules
Hereditary Angioedema
Peramivir 200 mg
Influenza
BCX7353
Hereditary Angioedema
Peramivir
Influenza
Peldesine
HIV Infections
forodesine HCl
Chronic Lymphocytic Leukemia (CLL)
forodesine hydrochloride
Lymphoma
Placebo
Paroxysmal Nocturnal Hemoglobinuria (PNH)
BCX17725
Netherton Syndrome
BCX10013
Paroxysmal Nocturnal Hemoglobinuria
Peramivir 150mg
Influenza
BCX4161
Hereditary Angioedema
Eculizumab
Paroxysmal Nocturnal Hemoglobinuria (PNH)
berotralstat
Hereditary Angioedema
BCX4430
Filovirus Infections
Peramivir 150 mg
Influenza
Peramivir+SOC
Cough
ulodesine
Gout
avoralstat
Diabetic Macular Edema (DME)
Galidesivir
COVID-19
BCX7353 and probes
Hereditary Angioedema
Forodesine 200 mg
Cutaneous T-cell Lymphoma (CTCL),
BCX-1777
Leukemia, Lymphocytic
forodesine hydrochloride (BCX-1777)
B-cell Acute Lymphoblastic Leukemia

Recent & active trials

NCTDrugPhaseStatusPrimary completion
NCT04933721berotralstatPhase 3Enrolling By Invitation2031-08-01
NCT06539507BCX17725Phase 1Recruiting2026-10-01
NCT07228559avoralstatPhase 1Terminated2026-04-17
NCT05741346BCX9930Phase 2Terminated2025-01-31
NCT06100900BCX10013Phase 1Completed2024-12-11
NCT05453968berotralstatPhase 3Active Not Recruiting2024-09-11
NCT04702568BCX9930Phase 2Terminated2023-10-04
NCT05116787PlaceboPhase 2Terminated2023-09-18
NCT05116774EculizumabPhase 2Terminated2023-09-14
NCT05162066BCX9930Phase 2Terminated2022-09-23
NCT03472040BCX7353Phase 3Completed2022-04-27
NCT03873116BCX7353 capsulesPhase 3Completed2021-07-08
NCT03891420GalidesivirPhase 1Terminated2021-01-31
NCT04330534BCX9930Phase 2Completed2020-11-11
NCT02369159PeramivirPhase 3Completed2019-10-28
NCT03800173GalidesivirPhase 1Completed2019-04-30
NCT03485911BCX7353 capsulesPhase 3Completed2019-04-10
NCT03240133BCX7353Phase 2Completed2019-01-29
NCT02635724PeramivirPhase 3Completed2018-04-01
NCT03136237BCX7353Phase 1Completed2017-08-15

Recent catalysts

FDA approvalDec 12, 2025· 176d ago
$BCRXBIOCRYST PHARMACEUTICALS INC
orladeyo
“the U.S. Food and Drug Administration has approved the Company\'s new drug application for the use of an oral pellet formulation of once-daily ORLADEYO ® (berotralstat) for prophylactic therapy in pediatric patients with hereditary angioedema aged 2 to <12 years”
PDUFADec 12, 2025· 176d ago· success
$BCRXBIOCRYST PHARMACEUTICALS INC
orladeyo
“The new PDUFA target action date is December 12, 2025.”
FDA approvalDec 11, 2025· 177d ago· success
$BCRXBIOCRYST PHARMACEUTICALS INC
orladeyo
“openFDA ORIG (TYPE 3) approval of ORLADEYO — application NDA219776”
PDUFASep 12, 2025· 267d ago· unknown
$BCRXBIOCRYST PHARMACEUTICALS INC
orladeyo (berotralstat) · Hereditary angioedema (HAE) in pediatric patients aged 2 to 11 years
“The FDA also granted priority review of the application, with a Prescription Drug User Fee Act ("PDUFA") target action date of September 12, 2025.”
NDA/BLA filedMay 14, 2025· 388d ago· unknown
$BCRXBIOCRYST PHARMACEUTICALS INC
orladeyo (berotralstat) · Hereditary angioedema (HAE) in pediatric patients aged 2 to 11 years
“the U.S. Food and Drug Administration ("FDA") has accepted its new drug application for the use of once-daily ORLADEYO® (berotralstat) oral granules in pediatric patients with hereditary angioedema ("HAE") aged 2 to 11 years.”